Gopinath Nagaraj | Pharmacology | Best Researcher Award

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Luana Fioriti | Pharmacology | Best Researcher Award

Assoc. Prof. Dr. Luana Fioriti | Pharmacology | Best Researcher Award

Laboratory Director at Istiuto di Riceerche Farmacologiche Mario Negri | Italy

Assoc. Prof. Dr. Luana Fioriti is a distinguished neuroscientist recognized for her groundbreaking research on prion-like proteins, synaptic plasticity, and neurodegenerative disorders. She has served in leading roles at Columbia University and the “Mario Negri” Institute in Milan, where she heads her laboratory in the Department of Neuroscience. With extensive expertise in protein aggregation, memory mechanisms, and disease-related pathways, Dr. Fioriti has contributed significantly to advancing knowledge in molecular neuroscience. Her pioneering work has been published in leading scientific journals and supported by prestigious awards and fellowships. She continues to drive innovation in translational neurobiology research.

Publication Profile 

Orcid

Education 

Assoc. Prof. Dr. Luana Fioriti earned her PhD in Neuroscience at the Mario Negri Institute and Open University, Italy, where she investigated abnormal forms of prion proteins in inherited prion diseases. She completed a Master’s in Biotechnological Applications at the University of Milan with summa cum laude honors, and a degree in Biological Sciences, majoring in Molecular Biology, also with summa cum laude, from the same university. Early in her career, she trained at the Mario Negri Institute’s Laboratory of Neurodegenerative Disorders, under Dr. Gianluigi Forloni, where she developed her expertise in prion biology, neurotoxicity, and mechanisms underlying neurodegenerative diseases.

Experience 

Assoc. Prof. Dr. Luana Fioriti has held prominent academic and research positions in both Italy and the United States. She currently serves as Head of Laboratory at the Department of Neuroscience, Mario Negri Institute, Milan, and Adjunct Associate Research Scientist at Columbia University. She has conducted extensive work in the laboratories of Nobel Laureate Eric Kandel and Dr. Ottavio Arancio at Columbia. Previously, she was an Associate Research Scientist at the Howard Hughes Medical Institute. Her career reflects a consistent focus on molecular neuroscience, protein biology, and translational approaches to neurodegenerative disorders, combining leadership, mentorship, and cross-institutional scientific collaboration.

Awards and Honors 

Assoc. Prof. Dr. Luana Fioriti has been recognized with numerous fellowships and awards for her contributions to neuroscience. Early in her career, she received fellowships from the University of Milan, the Italian Institute for University Study, and the Mario Negri Institute. She was awarded a scholarship to present at the World Alzheimer Congress and fellowships from Fondazione Monzino and the Italian Academy for Advanced Studies at Columbia University. She earned the Columbia Mentorship Award, the Telethon Career Development Award, and the AIMS Award for identifying SARS-CoV-2 protein inhibitors. These honors highlight her outstanding research leadership and impact in neurobiology.

Research Focus 

Assoc. Prof. Dr. Luana Fioriti research focuses on the molecular mechanisms of neurodegenerative diseases and memory persistence, with a particular emphasis on prion-like proteins, SUMOylation, ubiquitination, and tau pathology. Her work explores how protein aggregation and regulation influence synaptic plasticity and memory storage, contributing to both normal physiology and disease pathology. She has advanced understanding of prion biology, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Through translational neuroscience, she investigates SUMO mimetics and small molecules as therapeutic candidates for dementia and other neurodegenerative disorders. Her research integrates cell models, animal systems, and cutting-edge molecular approaches to identify potential drug targets.

Publication Top Notes

Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin

SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2

Structure of a reversible amyloid fibril formed by the CPEB3 prion-like domain reveals a core sequence involved in translational regulation

A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo

Liquid-Liquid Phase Separation in Physiology and Pathophysiology of the Nervous System

Ubiquitination and SUMOylation of amyloid and amyloid-like proteins in health and disease

Neuronal Localization of SENP Proteins with Super Resolution Microscopy

CPEB3 inhibits translation of mRNA targets by localizing them to P bodies

Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain

SUMOylation Is an Inhibitory Constraint that Regulates the Prion-like Aggregation and Activity of CPEB3

The Persistence of Hippocampal-Based Memory Requires Protein Synthesis Mediated by the Prion-like Protein CPEB3

Conclusion

Based on her extensive and innovative contributions in neuroscience, neurodegenerative disorders, and translational molecular biology, Dr. Luana Fioriti is an excellent candidate for the Best Researcher Award. Her ability to integrate fundamental discoveries with therapeutic implications, coupled with her international recognition, patents, and leadership in cutting-edge research, make her highly deserving of this honor. With continued expansion of her global visibility and interdisciplinary collaborations, she is poised to make even greater contributions to the scientific community and global health.

Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile 

Education 

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience 

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards 

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus 

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.